标题
EZH2: a novel target for cancer treatment
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-28
DOI
10.1186/s13045-020-00937-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- MiRNA-506 presents multiple tumor suppressor activities by targeting EZH2 in nasopharyngeal carcinoma
- (2020) Da-Chuan Fan et al. AURIS NASUS LARYNX
- A LYSA Phase Ib Study of tazemetostat (EPZ-6438) plus R-CHOP in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis features
- (2020) Clémentine Sarkozy et al. CLINICAL CANCER RESEARCH
- The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity
- (2020) Simona Pellecchia et al. Cancers
- Targeting epigenetics in sarcomas through EZH2 inhibition
- (2020) Antoine Italiano Journal of Hematology & Oncology
- EZH2 promotes gastric cancer cells proliferation by repressing p21 expression
- (2019) Jiewei Xu et al. PATHOLOGY RESEARCH AND PRACTICE
- EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells
- (2019) Shuo Huang et al. CANCER RESEARCH
- Enhancer of zeste homolog 2 (EZH2) regulates adipocyte lipid metabolism independent of adipogenic differentiation: Role of apolipoprotein E
- (2019) Nicole K. H. Yiew et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
- (2019) Kai-li Zhang et al. ACTA PHARMACOLOGICA SINICA
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
- (2019) Denarda Dangaj et al. CANCER CELL
- Epigenetic Modification of Enhancer of Zeste Homolog 2 Modulates the Activation of Dendritic Cells in Allergen Immunotherapy
- (2019) Hang Li et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
- (2019) Xinyin Liu et al. Molecular Therapy-Nucleic Acids
- Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors
- (2019) Timothy A. Yap et al. CLINICAL CANCER RESEARCH
- Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers
- (2019) Liye Zhou et al. CLINICAL CANCER RESEARCH
- The role and prospect of JMJD3 in stem cells and cancer
- (2019) Xiaojiao Yin et al. BIOMEDICINE & PHARMACOTHERAPY
- Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
- (2019) Alison Hirukawa et al. Cell Reports
- EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer
- (2019) Lilong Xia et al. BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
- Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
- (2019) Lauren Krill et al. GYNECOLOGIC ONCOLOGY
- CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-κB-miR-21 pathways
- (2018) Su-Jie Ni et al. Journal of Hematology & Oncology
- The polycomb group protein EZH2 induces epithelial–mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter
- (2018) Lu Gan et al. Journal of Hematology & Oncology
- Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
- (2018) Lixin Wan et al. MOLECULAR CELL
- ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer
- (2018) Peijing Zhang et al. Cell Reports
- Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways
- (2018) Takahiro Ito et al. Cell Reports
- Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
- (2018) David Wang et al. Cell Reports
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
- (2018) Xun Huang et al. CELL
- Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
- (2018) Sangeeta Goswami et al. JOURNAL OF CLINICAL INVESTIGATION
- miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer
- (2018) Jing Sun et al. ONCOGENE
- Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds
- (2018) Rossella Fioravanti et al. CHEMICAL RECORD
- Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells
- (2018) Youping Yang et al. OncoTargets and Therapy
- Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
- (2018) Jung Kim et al. Cell Reports
- Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
- (2017) Yanxiao Wang et al. International Journal of Biological Sciences
- CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion
- (2017) Xin Jin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
- (2017) Pei-Pei Kung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Telomerase reverse transcriptase (TERT) - enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and DNA damage responses in glioblastoma
- (2017) Fahim Ahmad et al. JOURNAL OF NEUROCHEMISTRY
- EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment
- (2017) Yatao Yin et al. Journal of Neuroinflammation
- An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
- (2017) Wei Qi et al. Nature Chemical Biology
- Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis
- (2017) Tao Tao et al. ONCOLOGY REPORTS
- The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer
- (2016) Zhongwei Li et al. CELL DEATH AND DIFFERENTIATION
- Emerging roles for Polycomb proteins in cancer
- (2016) Diego Pasini et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- The Functions of Histone Modification Enzymes in Cancer
- (2016) Ruilin Wang et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies
- (2016) Goro Sashida et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Loss ofEzh2synergizes withJAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
- (2016) Takafumi Shimizu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs
- (2016) Xiaofeng Wang et al. Journal of Hematology & Oncology
- Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
- (2016) Rishi G. Vaswani et al. JOURNAL OF MEDICINAL CHEMISTRY
- SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer
- (2016) W Lu et al. ONCOGENE
- Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer
- (2016) Xuejiao Song et al. Scientific Reports
- Pseudo-Reference-Based Assembly of Vertebrate Transcriptomes
- (2016) Kyoungwoo Nam et al. Genes
- Discovery, design, and synthesis of indole-based EZH2 inhibitors
- (2015) Victor S. Gehling et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction
- (2015) Ende Zhao et al. NATURE IMMUNOLOGY
- Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity
- (2015) Jie Yin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
- (2015) John E. Campbell et al. ACS Medicinal Chemistry Letters
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer
- (2015) Huiming Chen et al. Oncotarget
- Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia
- (2014) B. Xu et al. BLOOD
- EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells
- (2014) Bryson W Katona et al. CANCER BIOLOGY & THERAPY
- Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2
- (2014) Xiangqian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
- (2014) Sarah K. Knutson et al. PLoS One
- An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
- (2013) Kyle D. Konze et al. ACS Chemical Biology
- Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
- (2013) Eunhee Kim et al. CANCER CELL
- The Polycomb Protein Ezh2 Regulates Differentiation and Plasticity of CD4+ T Helper Type 1 and Type 2 Cells
- (2013) Damon J. Tumes et al. IMMUNITY
- Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
- (2013) Woojin Kim et al. Nature Chemical Biology
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ezh1 Is Required for Hematopoietic Stem Cell Maintenance and Prevents Senescence-like Cell Cycle Arrest
- (2012) Isabel Hidalgo et al. Cell Stem Cell
- PRC2 directly methylates GATA4 and represses its transcriptional activity
- (2012) A. He et al. GENES & DEVELOPMENT
- EZH2 couples pancreatic regeneration to neoplastic progression
- (2012) J. Mallen-St. Clair et al. GENES & DEVELOPMENT
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
- (2012) Sarah K Knutson et al. Nature Chemical Biology
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
- (2012) Panagiotis Ntziachristos et al. NATURE MEDICINE
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- (2012) W. Qi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
- (2012) Sharad K. Verma et al. ACS Medicinal Chemistry Letters
- EZH2 Y641 mutations in follicular lymphoma
- (2011) C Bödör et al. LEUKEMIA
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Regulation of Tumor Angiogenesis by EZH2
- (2010) Chunhua Lu et al. CANCER CELL
- BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer
- (2010) Xiao-Wei Zhang et al. Molecular Cancer
- Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression
- (2009) Z L Wu et al. CELL DEATH AND DIFFERENTIATION
- DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
- (2009) T. B. Miranda et al. MOLECULAR CANCER THERAPEUTICS
- EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency
- (2008) Xiaohua Shen et al. MOLECULAR CELL
- Roles of the EZH2 histone methyltransferase in cancer epigenetics
- (2008) Jeffrey A. Simon et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started